In clinical practice, breast cancer is considered to consist of four different molecular subtypes: hormone receptor-positive (consisting of luminal A, and luminal B subtypes), human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC) [2, 3]. Here, ERBB2 is linked to triple-negative breast carcinoma.